Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 18/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | QPCT | Q16769 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16286260 | 1.00 | NAMPT (0.54) | NAMPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL16286244 | 0.99 | NAMPT (0.53) | NAMPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL16286245 | 0.99 | NAMPT (0.53) | NAMPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL16286300 | 0.97 | NAMPT (0.55) | NAMPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL16286301 | 0.97 | NAMPT (0.55) | NAMPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL14324397 | 0.93 | NAMPT (0.56) | NAMPTQPCT | |
| SCHEMBL14324396 | 0.93 | NAMPT (0.56) | NAMPTQPCT | |
| SCHEMBL17311797 | 0.93 | NAMPT (0.56) | NAMPTQPCT | |
| SCHEMBL14324806 | 0.90 | NAMPT (0.53) | NAMPTCYP3A4CYP2D6QPCT | |
| SCHEMBL14324807 | 0.90 | NAMPT (0.53) | NAMPTCYP3A4CYP2D6QPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160367541-A1 | THERAPEUTIC AND DIAGNOSTIC METHODS | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2016-12-22 | — | — | US | disclosed |
| US-8912184-B1 | Therapeutic and diagnostic methods | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2014-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160367541-A1 | THERAPEUTIC AND DIAGNOSTIC METHODS | NAMPT, NAPRT, NNT | NAMPT 1/4885CYP3A4 3891/4885CYP2D6 3718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.